CHATSWORTH, Calif., May 20, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Thomas E. Warekois, Corporate Vice President and President of the Iris Diagnostics division, and Thomas H. Adams, Ph.D., Corporate Vice President and Chief Technology Officer, will be available for one-on-one meetings with institutional investors at the 7th Annual Craig-Hallum Institutional Investor Conference on Wednesday, June 2, 2010, at the Radisson Plaza Hotel in Minneapolis, Minnesota.
The conference is for clients of Craig-Hallum. To schedule a one-on-one or for more information, please contact your Craig-Hallum sales representative, or visit www.Craig-Hallum.com.
More than 75 companies from a variety of industries, including medical device manufacturers, will participate in the conference sponsored by Craig-Hallum, an institutional equity and investment-banking firm. During the conference, executives from each company will participate in private one-on-one sessions with select institutional investors.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,700 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.